Data science in early drug discovery – getting it right from the start

The application of data science in the early stages of drug development is not new – progress in algorithms and computing power has been ongoing for years. We have reached the point where we have to reflect on the road travelled and look forward to upcoming opportunities and challenges. To further pave the way and reach the top in health data science, stakeholders will have to find each other and work together. Once everyone is on board, data science knows no bounds!
Mark Hicken is Vice President of Strategy for Europe, Middle East and Africa (EMEA) at the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen). With more than 20 years of experience in the company, Mark leads a cross-functional team that drives Janssen’s continued growth across the region, in close collaboration with the local operating companies. On the 28th of October, Mark presented a talk during an online event hosted by Johnson & Johnson Innovation – JLABS (JLABS) ‘Start at the End: Thinking Commercial during Discovery and Development’ (recording available here). Following the webinar, Mark shared some additional insights and advice with us.
Pharmaceutical company Janssen Pharmaceutica and gin distillery Filliers Distillery are making disinfectant hand gel from Sunday. They will distribute it among the Belgian hospitals.